RNS Number : 4353E MaxCyte, Inc. 29 June 2023 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 3045E MaxCyte, Inc. 29 June 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , June 29, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
RNS Number : 3020E MaxCyte, Inc. 29 June 2023 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 7871D MaxCyte, Inc. 23 June 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options ROCKVILLE, MD , June 23, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 7204D MaxCyte, Inc. 23 June 2023 Result of AGM Rockville, MD , June 23, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
RNS Number : 6635D MaxCyte, Inc. 23 June 2023 Result of AGM Rockville, MD , June 23 , 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
RNS Number : 4553D MaxCyte, Inc. 21 June 2023 Publication of Annual Report ROCKVILLE, MD , June 21, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
RNS Number : 0358D MaxCyte, Inc. 16 June 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing Gaithersburg, Maryland - 16 June 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 3691B MaxCyte, Inc. 02 June 2023 MaxCyte to Participate in Upcoming Investor Conferences Rockville, MD , June 2, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative
ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development
